Blue Diamond
1. NSCLC : Patient Management in Real Practices After the Reimbursement Approval of KEYTURUDA in the 1st line mNSCLC Treatment
2. TNBC : New indication for high risk early TNBC patients which is Neoadjuvant-adjuvant treatment based on KEYNOTE-522
| Address | 23Fl Seoul Square Building 416, Hangang-daero, Jung-gu, Seoul, 04637, Korea | ||
|---|---|---|---|
| Telephone | +8223312000 | Fax | +8223312000 |
| Website | https://www.msd-korea.com/ | eunhyun.lee@merck.com | |
We aspire to be the premier research-intensive biopharmaceutical company in the world. For 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.
KEYTRUDA is a selective monoclonal antibody that blocks the programmed cell death-1 (PD-1) protein pathway, potentiating T-cell responses, including anti-tumour responses. KEYTRUDA reactivates tumour-specific cytotoxic T lymphocytes and anti-tumour immunity. as of May 19 2022, Keytruda got regulatory approval for 20 indications in 11 tumor types
